aTyr Pharma to Participate in September Investor Conferences

Rhea-AI Summary

aTyr Pharma, a clinical stage biotechnology company, announced its participation in three investor conferences in September 2024. These include the Wells Fargo Healthcare Conference on September 5 in Everett, MA (1x1 investor meetings), the H.C. Wainwright 26th Annual Global Investment Conference on September 11 in New York, NY (corporate presentation at 10:30am EDT), and the Cantor Fitzgerald Global Healthcare Conference on September 18 in New York, NY (corporate presentation at 1:55pm EDT).

Webcasts of the H.C. Wainwright and Cantor Fitzgerald presentations will be available on aTyr's website for at least 90 days. The company's management will also be available for one-on-one meetings with registered conference attendees. aTyr focuses on developing therapies for fibrosis and inflammation using tRNA synthetase biology, with their lead candidate efzofitimod targeting interstitial lung disease.

SAN DIEGO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in several upcoming investor conferences scheduled to take place in September 2024.

Details of the conferences appear below:

Conference: Wells Fargo Healthcare Conference
Date: Thursday, September 5, 2024
Location: Everett, MA
Format: 1x1 Investor Meetings

Conference: H.C. Wainwright 26^th Annual Global Investment Conference
Date: Wednesday, September 11, 2024
Time: 10:30am EDT
Location: New York, NY
Format: Corporate Presentation

Conference: Cantor Fitzgerald Global Healthcare Conference
Date: Wednesday, September 18, 2024
Time: 1:55pm EDT
Location: New York, NY
Format: Corporate Presentation

In addition to the presentations, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conferences. A webcast of the H.C. Wainwright and Cantor Fitzgerald presentations will be available on the Investor’s section of the company’s website at www.atyrpharma.com. Following the events, a replay of the presentations will be available on the aTyr website for at least 90 days. For more information, contact investorrelations@atyrpharma.com.

About aTyr

aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.

Contact:

Ashlee Dunston

Director, Investor Relations and Public Affairs

adunston@atyrpharma.com

FAQ

What investor conferences will aTyr Pharma (ATYR) attend in September 2024?

aTyr Pharma will attend three investor conferences in September 2024: Wells Fargo Healthcare Conference on September 5, H.C. Wainwright 26th Annual Global Investment Conference on September 11, and Cantor Fitzgerald Global Healthcare Conference on September 18.

When and where will aTyr Pharma (ATYR) present at the H.C. Wainwright conference?

aTyr Pharma will present at the H.C. Wainwright 26th Annual Global Investment Conference on Wednesday, September 11, 2024, at 10:30am EDT in New York, NY.

Will aTyr Pharma (ATYR) provide webcasts of their September 2024 conference presentations?

Yes, aTyr Pharma will provide webcasts of their presentations at the H.C. Wainwright and Cantor Fitzgerald conferences. These will be available on the company's website for at least 90 days after the events.

What is aTyr Pharma's (ATYR) lead therapeutic candidate?

aTyr Pharma's lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease.

What is the focus of aTyr Pharma's (ATYR) research and development?

aTyr Pharma focuses on translating tRNA synthetase biology into new therapies for fibrosis and inflammation, using a discovery platform that uncovers signaling pathways driven by domains derived from all 20 tRNA synthetases.